首页>
外国专利>
MUTATIONS DEFINE CLINICAL SUBGROUPS OF GLIOMAS
MUTATIONS DEFINE CLINICAL SUBGROUPS OF GLIOMAS
展开▼
机译:突变定义了胶质瘤的临床亚群
展开▼
页面导航
摘要
著录项
相似文献
摘要
Genetic signatures capable of distinguishing among several types of gliomas provide clinically relevant information that can serve as an adjunct to histopathological diagnosis. For example, mutations in the TERT promoter occurred in 74.2% of glioblastomas (GBM), but occurred in a minority of Grade II-III astrocytomas (18.2%). In contrast, IDH1/2 mutations were observed in 78.4% of Grade II-III astrocytomas, but were uncommon in primary GBM. The genetic signatures permit the stratification of the glioma patients into distinct cohorts.
展开▼